EGFR and non-small cell lung carcinoma: Neoadjuvant or perioperative chemotherapy plus an ICI would now be the preferred approach for resectable stage III NSCLC for the majority of patients unless they have tumours with molecular abnormalities, such as EGFR or ALK, or have contraindications to the use of an ICI.